

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandra, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/919,486	07/31/2001	Alexander N. Glazer	B01-114-1	3672	
23379	7590 11/26/2003		EXAMINER		
	ARON OSMAN ND TECHNOLOGY LAW (ROBINSON, HOPE A			
	DENISE DRIVE		ART UNIT	PAPER NUMBER	
HILLSBORO	OUGH, CA 94010		1653		
			DATE MAILED: 11/26/200	3	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application	on No	Applicant(s)				
Office Action Summary	09/919,48 Examin r		GLAZER ET AL. Art Unit				
•	Hope A. F		1653				
Th MAILING DATE of this communication app			L	ldress			
Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status							
1) Responsive to communication(s) filed on 22 S	<u>eptember 2</u>	<u>'003</u> .					
2a)⊠ This action is FINAL . 2b)☐ This	action is no	on-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
 4) Claim(s) 1-22 is/are pending in the application. 4a) Of the above claim(s) 15, 19-22 is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 1-14 and 16-18 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement. 							
Application Papers							
9) The specification is objected to by the Examiner.							
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. §§ 119 and 120							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 13) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78. a) The translation of the foreign language provisional application has been received. 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78. 							
Attachment(s)							
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s)		4) Interview Summary (5) Notice of Informal Pa (6) Other:					

Application/Control Number: 09/919,486 Page 2

Art Unit: 1653

DETAILED ACTION

1. Applicant's response to the Office Action mailed May 7, 2003 on September 22, 2003 is

acknowledged.

2. Claims 23-24 have been canceled. Claims 13-15 and 17 have been amended. Claims 1-

22 are pending. Claims 1-14 and 16-18 are under examination.

3. The amendment filed September 22, 2003, states the restriction requirement has been

confirmed, however, applicant states that claim 15 should be rejoined because the location or

context of the same claimed cell should not be grounds for characterizing separate and distinct.

This argument however, is not persuasive because if a cell is in a dish versus in an organism will

acquire a different status in the art which exemplifies burden of search. Claim 15 merely recites

in situ which could read on gene therapy. Therefore, the search would not be co-extensive. The

MPEP in chapter 800 states that restriction requirement is proper if an invention can be shown to

be independent and or distinct. Therefore, applicant's comments are noted, but are not persuasive

thus the restriction requirement is deemed proper in accordance with the MPEP and is thus final.

4. The objection to the Specification has been withdrawn. The following rejections are or

remain applicable:

Claim Rejections - 35 U.S.C. § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

Application/Control Number: 09/919,486 Page 3

Art Unit: 1653

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

5. Claims 1-14 and 16-18 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 and the dependent claims hereto are indefinite as the components of the fusion protein are "a first holo-phycobiliprotein domain and a heterologous protein domain" and the metes and bound as to what "heterologous protein domain" is undefined in the claim(s) and in the specification. The claim is further indefinite as to which components in the list, the cell "makes or comprises". Claim 1 is indefinite as to "a first holo-phycobiliprotein" as this claim language implies a "second" which is not recited in the claim. Claim 1 is also indefinite as to the language "corresponding", corresponding to what? Claim 1 appears to be incomplete as claims 2-4 recite a component needed to form the bilin recited in this claim. Note the following: A recombinant prokaryotic or eukaryotic cell which expresses a holo-phycobiliprotein fusion protein comprising a fluorescent, heterologous to the cell first holo-phycobiliprotein domain fused to a fluorescent, heterologous to the cell second holo-phycobiliprotein domain, comprising the following components: a heme, a recombinant heme oxygenase, a bilin, a recombinant bilin reductase, a recombinant phycobiliprotein domain-bilin lyase, an apo-phycobiliprotein fusion protein precursor consisting of a apo-phycobiliprotein domain, wherein, said components react inside the cell to form the holo-phycobiliprotein fusion protein. It is suggested that applicant

Application/Control Number: 09/919,486 Page 4

Art Unit: 1653

cancel claims 2 and 3 and rewrite claim 4 to recite "The cell of claim 1 wherein the heme oxygenase is HO1" in view of the above proposed claim language.

Claims 5-9 are indefinite as to the recitation of "...spectroscopically distinguishable" as it is unclear how much variation (i.e. sensitivity of the equipment) is required, further, spectroscopic differences also vary based on the operator of the equipment.

Claim Rejections - 35 U.S.C. § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art arc such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 6. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103 (a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103 (c) and potential 35 U.S.C. 102 (f) or (g) prior art under 35 U.S.C. 103 (a).

Art Unit: 1653

7. Claims 1-14 and 16-18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Fairchild et al. (PNAS, vol. 89, pages 7017-7021, April 1992) taken with Allnutt et al. (U.S. Patent/PUB No. 20010055783, June 16, 2001) and Frankenberg et al. (The Plant Cell, vol. 13, pages 965-978, April 2001).

Fairchild et al. teach phycobiliproteins expressed in recombinant Escherichia coli cells (page 7017 and abstract). Fairchild et al. disclose proteins having the apo-subunit and the holo-subunit of a heterologous C-phycocyanin (abstract and page 7017). Fairchild et al. also disclose the bilin phycocyanobilin (PCB) and the protein bilin lyase CpcE and CpcF (phycocyanin subunit phycocyanobilin lysase) see pages 7017-7018 and 7020). Fairchild et al. teach that heme is a component in the bilin biosynthesis pathway (page 7017 and abstract). Fairchild et al. does not teach a fusion protein (see pages 7017-7020). However, Allnutt et al. teach fusion proteins which have a phycobiliprotein domain and another domain corresponding to a first member of a specific binding pair, where the domain derived from the first member of the specific binding pair can be directly fused to the phycobiliprotein domain, expressed in E. coli (see abstract and page 6). Allutt et al. also teach that phycobiliprotein is a fluorescent label for other proteins and as an in situ probe (page 6). Allnutt et al. further teaches that phycobiliprotein domains have bilin prosthetic groups (6). In-so-far-as Fairchild et al. and Allnutt et al. do not explicitly teach PcyA, Frankenberg et al. teaches this enzyme and the specific pathway (page 967). Frankenberg et al. teach that phytobilins are synthesized from heme via the intermediacy of biliverdin, the interconversion is accomplished by ferredoxin dependent heme oxygenases (page abstract and 965). Frankenberg et al. also teach that cyanobacteria and red algae possess novel ferredoxin dependent bilin reductases for the synthesis Application/Control Number: 09/919,486

Art Unit: 1653

486 Page 6

of the linear tetrapyrrole precursors such as PcyA (3Z-phycocyanobilin:ferredoxin oxidoreductase). Frankenberg et al. also teach a fusion protein (see pages 965-967).

Therefore, it would have been obvious to one of ordinary skill in the art to have the claimed invention as a whole by combining the teachings of the above references because all three references teach phycobiliproteins (a family of proteins found in cyanobacteria, red algae etc.) and the expression of the protein in recombinant E. coli cells. In addition, Fairchild et al. teach the holo and apo subunits of the protein. One of ordinary skill would be motivated to combine the teachings of the references because Frankenberg et al. teach the specific pathway by which phytobilins are synthesized and the utilization of the specific enzymes recited in the claims. Moreover, although the references by Fairchild et al. and Allnutt et al. do not explicitly teach the enzymes Frankenberg demonstrates that the enzymes are a part of the pathway to obtain the end product which is taught by the all three references and claimed in the instant application. The claimed invention is within the art as Fairchild et al. teach phycobiliproteins having apo and holo subunits expressed in a recombinant cell (E. coli) and Allnutt et al. teach a recombinant cell expressing phycobiliprotein fusion protein as claimed in claim 1, and Frankenberg teaches the claimed enzymes and the pathway of the biosynthesis of bilin, indicating that the enzymes recited in claim 1 are intrinsic properties. Thus, the claimed invention was obvious to make and use at the time it was made and was prima facie obvious.

Conclusion

8. No claims are allowable.

Application/Control Number: 09/919,486

Art Unit: 1653

9. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Page 7

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Hope A. Robinson whose telephone number is (703) 308-6231. The Examiner can normally be reached on Monday- Friday from 9:00 A.M. to 6:30 P.M. (EST).

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor Christopher S.F. Low, can be reached at (703) 308-2932.

Any inquiries of a general nature relating to this application should be directed to the Group Receptionist whose telephone number is (703) 308-0196.

Papers related to this application may be submitted by facsimile transmission. The official fax phone number for Technology Center 1600 is (703) 308-2742. Please affix the Examiner's name on a cover sheet attached to your communication should you choose to fax

Application/Control Number: 09/919,486

Art Unit: 1653

Page 8

your response. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG (November 15, 1989).

Hope A. Robinson, MS

Patent Examiner

Karen Cochrane Carlson, Ph.D